BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Posted on: January 21, 2011
Jan. 19, 2011—BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.
To read full press release, please click here.
For more information, visit clinicaltrials.gov.